Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

As Merck has been hinting at more (and relatively ... is an important element to continue to execute on the corporate strategy. The cash flow statement (shown below) indicated the company ...

The deal represents a second strategic co-marketing deal for Merck in oncology, which has created a similar $8.5bn alliance with AstraZeneca on its PARP inhibitor drug Lynparza, which will also be ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko ...

Additionally, positive Phase 3 trial results for the HIV-1 treatment DOR/ISL further underscore Merck's progress in drug development. Strategic efforts like the FDA's priority review for KEYTRUDA ...

Merck is also developing a subcutaneous formulation of Keytruda that can extend its patent life. MRK’s Pipeline Progress & Strategic M&A Deals Merck made meaningful regulatory and clinical ...